Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of 4.00
Press release Maxim Group initiates the coverage of the CROSSJECT share with…
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease…
Atos Group receives confirmatory offer from the French State to acquire part of its former Advanced Computing business
Press release Atos Group receives confirmatory offer from the French State to…